- Trials with a EudraCT protocol (2,502)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (429)
2,502 result(s) found for: Cardiovascular diseases.
Displaying page 5 of 126.
EudraCT Number: 2014-001319-38 | Sponsor Protocol Number: MW051 | Start Date*: 2015-09-24 |
Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG | ||
Full Title: Monocenter prospective open single-arm phase IV study of the effects of hawthorn extract WS® 1442 on arterial micro-vascular structure and macro-vascular function, persistance and erectile functio... | ||
Medical condition: Underlying cardiovascular disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-004662-25 | Sponsor Protocol Number: AMI-Study | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Krakowski Szpital Specjalistyczny im. Jana Pawła II | |||||||||||||
Full Title: Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Resear... | |||||||||||||
Medical condition: AMI: Acute Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004180-43 | Sponsor Protocol Number: BAY59-7939/15786 | Start Date*: 2013-03-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People u... | |||||||||||||
Medical condition: Prevention of major cardiovascular events in patients with coronary or peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) CZ (Completed) FI (Completed) IT (Completed) HU (Completed) NL (Completed) GB (Completed) SK (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004894-25 | Sponsor Protocol Number: ATCC10AA_IS_ICDJ10-J18 | Start Date*: 2009-06-30 |
Sponsor Name:Karolinska University Hospital Huddinge | ||
Full Title: Effect of rosuvastatin on cardiovascular events and mortality after pneumonia | ||
Medical condition: Community aquired pneumonia | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002954-35 | Sponsor Protocol Number: EFC14828 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascul... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) LV (Completed) SE (Completed) NO (Completed) LT (Completed) EE (Completed) DK (Completed) ES (Completed) FI (Completed) BG (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004015-13 | Sponsor Protocol Number: FMD-TRI-2016-01 | Start Date*: 2017-02-20 | |||||||||||
Sponsor Name:Ferrer Internacional, S.A. | |||||||||||||
Full Title: A phase III, international, multicenter, randomized and openlabel study to evaluate the efficacy on LDLc and blood pressure reduction and safety of Trinomia® versus usual care in patients with high... | |||||||||||||
Medical condition: High cardiovascular risk without previous cardiovascular event. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004061-39 | Sponsor Protocol Number: CNTO1959PSO4015 | Start Date*: 2021-10-22 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) SE (Completed) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005317-40 | Sponsor Protocol Number: Herlev | Start Date*: 2021-05-27 |
Sponsor Name:Odense University Hospital - Department of Cardiology | ||
Full Title: Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): A randomized controlled trial | ||
Medical condition: Obese patients (BMI >28 kg/m2), aged 60-84 years, with documented cardiovascular disease but no history of diabetes mellitus or heart failure with reduced ejection fraction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005440-98 | Sponsor Protocol Number: | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:AKH Linz | |||||||||||||
Full Title: Double blinded randomised trial for the evaluation of the effectiveness of prophylactic use of sildenafil for the prevention of pulmonary hypertensive crisis after congenital heart surgery | |||||||||||||
Medical condition: Ventriculs septal defect, atrioventricular canal with pulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022970-14 | Sponsor Protocol Number: CACZ885M2301 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction... | |||||||||||||
Medical condition: atherosclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SE (Prematurely Ended) PL (Completed) LV (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) EE (Completed) GR (Completed) IS (Prematurely Ended) BE (Completed) NO (Completed) CZ (Completed) IT (Completed) BG (Prematurely Ended) SI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005032-42 | Sponsor Protocol Number: 17-162 | Start Date*: 2020-04-20 |
Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | ||
Full Title: Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease | ||
Medical condition: Diabetes Type 2 with existing cardiovascular disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-004303-32 | Sponsor Protocol Number: ASPIRIN-17 | Start Date*: 2017-04-20 |
Sponsor Name:VU university medical center | ||
Full Title: ASsesment of Platelet function and Inhibition in patients Recovering from severe INfection | ||
Medical condition: Hyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000334-17 | Sponsor Protocol Number: TRACK_001 | Start Date*: 2023-03-31 |
Sponsor Name:The George Institute of Global Health | ||
Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial | ||
Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003789-15 | Sponsor Protocol Number: 9.2 | Start Date*: 2019-12-17 |
Sponsor Name:Department of Cardiology, Hartcentrum, University Medical Center Groningen | ||
Full Title: Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands | ||
Medical condition: Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004616-36 | Sponsor Protocol Number: D5135C00001 | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic str... | |||||||||||||
Medical condition: peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) ES (Completed) DE (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002868-17 | Sponsor Protocol Number: 633765 | Start Date*: 2016-05-06 | |||||||||||
Sponsor Name:Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC) | |||||||||||||
Full Title: Secondary Prevention of Cardiovascular Disease in the Elderly | |||||||||||||
Medical condition: Secondary Prevention of Major Cardiovascular Events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in post MI cohort. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003895-65 | Sponsor Protocol Number: DAL-301 | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:DalCor Pharma UK Ltd, Leatherhead, Swiss Branch Zug | |||||||||||||
Full Title: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Sy... | |||||||||||||
Medical condition: This study is investigating the cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects wit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) SE (Completed) SK (Completed) DK (Completed) FI (Completed) PT (Completed) DE (Completed) HU (Completed) ES (Ongoing) AT (Completed) CZ (Completed) BG (Completed) RO (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005568-40 | Sponsor Protocol Number: LoDoCo2 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:Werkgroep Cardiologische centra Nederland | |||||||||||||
Full Title: Low-dose colchicine for secondary prevention of cardiovascular disease | |||||||||||||
Medical condition: cardiovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002134-31 | Sponsor Protocol Number: HLS14/01 | Start Date*: 2015-07-22 |
Sponsor Name:Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario | ||
Full Title: Evalutation of maraviroc therapy in PI-treated HIV+ patients at intermediate-low risk for cardiovascular diseases: a phase IV, randomized, open study | ||
Medical condition: HIV-1 infection. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
